Patients Are Waiting: Speeding Time to Treatment in Rare Disease
Companies are overcoming challenges to develop, launch, and educate on new rare disease medicines and treatment faster. Rare diseases are no longer rare. Every year,…
Clinical Trials
Current State of Drug Development, Clinical Trials, and Precision Measures
Drug research and development can cost up to $6bn per asset and take an average of 13 years from discovery to approval1. In this expensive…
Novel Drugs: The Case for Applied Behavioural Science in Driving Take up
Behavioural science’s time has come in the pharma industry, as medical communications adapt to a more ambitious and diverse treatment landscape. Here, Alpharmaxim’s William Hind…
Modern by (Trial) Design: Shedding Legacy EDC Systems to Gain Clinical Capacity
As trials become increasingly complex, companies share how leaving behind legacy EDC systems can save thousands of hours during study build and testing. In today’s…
Digital Tools can Help Patients and Healthcare Providers Navigate the Rapidly Changing Oncology Treatment Landscape
The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD and this number is…
Revolutionising Drug Development: Key Takeaways from the ICON Biotech Survey
In the dynamic landscape of biotechnology, ICON’s recent survey of over 100 leaders from the biotech industry dissects the challenges and opportunities faced by biotech…
Why Technology is Key to Unlocking Clinical Trial Access in Underserved Communities
Despite a step change in awareness about the need for diverse participants in clinical trials, ongoing clinical trials in western health systems fail to reflect…
The Problem with Clinical Trials (and how virtual insight-gathering can help)
These days, clinical trials are in the news pretty much daily. Whether successful or not, they can impact not only the perception of a pharmaceutical…
Survey Reveals Overwhelmingly Positive Early Experiences of EMA’s New Clinical Trials Information System
European and US pharma companies have welcomed the EMA’s new clinical trials information system (CTIS), according to an Arriello survey. Arriello’s Kieran O’Donnell and Nicola…
Virtual Tools for Promoting Diversity in Pharma and Clinical Trials
It is no secret that Pharma (still) has a major diversity problem. Not only on their own senior leadership teams but also in their clinical…